Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function

NCT05760300 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05760300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05760300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2023
Completion date
July 23, 2024
Enrollment
41 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d infection